The marker of adverse prognosis 1.5-anhydroglucitol in patients with coronary heart disease in the long-term period after planned myocardial revascularization

Abstract


Aim. Determination of the prognostic value of 1.5-anhydroglucitol (1.5-AG) for the development of cardiovascular events in patients with coronary heart disease (CHD) within a year after a planned percutaneous coronary intervention (PCI). Materials and methods. A prospective study was conducted in Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Disease among 149 patients admitted to planned PCI in the period from 2016 to 2017. Criteria for inclusion in the study: age up to 70 years, angina I-IV functional classes or post-infarction cardiosclerosis, the presence of indications for planned PCI. Exclusion criteria from the study: previous myocardial revascularization; prosthetic heart valves; decompensation of chronic heart failure, anemia of any degree; acute coronary syndrome in index hospitalization; exacerbation of somatic diseases. The results of the research were processed by Statistica Windows 6.0. Results. During the year after planned PCI, 39 (26.14%) cardiovascular events were registered in patients with CHD, of whom more than half of the cases (51.28%) were associated with the presence of indications for PCI of de novo. Lower levels of 1.5-AG were observed in the group of patients with cardiovascular events (p=0.000). When patients were divided according to median of the studied marker patients with a concentration of 1.5-AG less 20.96 μg/ml (before PCI) were more likely to have PCI after restenosis of the stent, compared with patients whose median concentration of this marker was higher (p=0.028). The logistic regression method revealed a significant direct relationship reflecting the prognostic value of lower concentration of 1.5-AG in relation to the development of cardiovascular events in patients regardless of the presence of carbohydrate metabolism disorders [OR 0.25 (0.10-0.62)]. Conclusion. According to the results of the study, the prognostic value of the concentration of 1.5-AG less 20.96 µg/ml was established in relation to the development of cardiovascular events in patients with CHD during the year after a planned PCI, regardless of the presence of carbohydrate metabolism disorders.

Full Text

Restricted Access

About the authors

Yu S Ignatova

Kemerovo State Medical University of the Ministry of Health of the Russian Federation

Email: julia-smolina@mail.ru
Kemerovo, Russia

V N Karetnikova

Kemerovo State Medical University of the Ministry of Health of the Russian Federation; Research Institute for Complex Issues of Cardiovascular Diseases

Kemerovo, Russia

A A Horlampenko

Kemerovo State Medical University of the Ministry of Health of the Russian Federation

Kemerovo, Russia

O V Gruzdeva

Research Institute for Complex Issues of Cardiovascular Diseases

Kemerovo, Russia

Yu A Dyleva

Research Institute for Complex Issues of Cardiovascular Diseases

Kemerovo, Russia

O L Barbarash

Kemerovo State Medical University of the Ministry of Health of the Russian Federation; Research Institute for Complex Issues of Cardiovascular Diseases

Kemerovo, Russia

References

  1. Дедов И.И., Шестакова М.В. Сахарный диабет в пожилом возрасте: диагностика, клиника, лечение. Практическое руководство для врачей. М.; 2011.
  2. Corpus R.A, O’Neill W.W, Dixon S.R, Timmis G.C, Devlin W.H. Relation of hemoglobin A1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol. 2003;92:1282-6. doi: 10.1016/j.amjcard.2003.08.008
  3. Ueda H, Mitsusada N, Harimoto K, Miyawaki M, Yasuga Y, Hiraoka H. Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug - eluting stent implantation in patients with diabetes mellitus. Cardiology. 2010;116(1):51-7. doi: 10.1159/000314331
  4. Ying L, He X, Ma X, Shen Y, Su H, Peng J, Wang Y, Bao Y, Zhou J, Jia W. Serum 1,5-anhydroglucitol when used with fasting plasma glucose improves the efficiency of diabetes screening in a Chinese population. Scientific Rep. 2017;7(1):11968. doi: 10.1038/s41598-017-12210-z
  5. Ouchi S, Shimada K, Miyazaki T, Takahashi S, Sugita Y, Shimizu M, Murata A, Kadoguchi T, Kato T, Aikawa T, Suda S, Sai E, Hiki M, Iwata H, Kasai T, Miyauchi K, Daida H. Low 1,5-anhydroglucitol levels are associated with long - term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0%. Cardiovasc Diabetol. 2017;16(1):151. doi: 10.1186/s12933-017-0636-1
  6. Stickle D, Turk J. A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol. 1997;273(4):821-30.
  7. Buse J.B, Freeman J.L, Edelman S.V, Jovanovic L, Mc Gill J.B. Serum 1,5-anhydroglucitol (GlycoMark ): a short - term glycemic marker. Diabetes Technol Ther. 2003;5(3):355-63. doi: 10.1089/152091503765691839
  8. Selvin E, Rawlings A, Lutsey P, Maruthur N, Pankow J.S, Steffes M, Coresh J. Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. Diabetes. 2016;65(1):201-8. doi: 10.2337/db15-0607
  9. Kim W.J, Park C.Y. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine. 2013;43(1):33-40. doi: 10.1007/s12020-012-9760-6
  10. Shiga Y, Kuriyama M, Kanaya Y, Takeshima S, Takemaru M, Takamatsu K, Shimoe Y, Fujikawa Y, Nishigaki M. Serum 1,5-Anhydroglucitol: Risk Factor of Acute Ischemic Stroke and Transient Ischemic Attack in Well-Controlled Diabetes. Cerebrovasc Dis. 2017;44(5-6):325-9. doi: 10.1159/000481626
  11. Takahashi S, Shimada K, Miyauchi K, Miyazaki T, Sai E, Ogita M, Tsuboi S, Tamura H, Okazaki S, Shiozawa T, Ouchi S, Aikawa T, Kadoguchi T, Al Shahi H, Yoshihara T, Hiki M, Isoda K, Daida H. Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first - time elective percutaneous coronary intervention. Cardiovasc Diabetol. 2016;15:145. doi: 10.1186/s12933-016-0459-5
  12. Wang Y, Yuan Y, Zhang Y, Lei C, Zhou Y, He J, Sun Z. Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community - based population at high risk of diabetes. Acta Diabetologica. 2017;54(5):425-31. doi: 10.1007/s00592-016-0944-z
  13. Warren B, Lee A.K, Ballantyne C.M, Hoogeveen R.C, Pankow J.S, Grams M, Köttgen A, Selvin E. Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study. Clin Chem. 2018;64(10):1536-7. doi: 10.1373/clinchem.2018.291773

Statistics

Views

Abstract - 40

PDF (Russian) - 12

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies